The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

Q4 2024 Management View Chris Viehbacher, CEO, noted that Biogen is focused on three core priorities: driving growth from its four recently launched products, reprioritizing the pipeline for ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to ...

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) ...